CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03941262
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:28.708604+00:00
Published At: 2023-11-13T00:00:00+00:00
Record Updated At: 2023-11-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Refractory Cancer", "Metastatic Cancer", "Recurrent Cancer", "Unresectable Carcinoma", "Solid Tumor, Adult", "Advanced Cancer", "Advanced Solid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-13"
protocolSection.identificationModule.nctId: "NCT03941262"
protocolSection.identificationModule.officialTitle: "Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.